Felodipine

Introduction Overview

Generic Name

Felodipine

Brand Name

Plendil

Dosage Form

Oral extended-release tablet (2.5 mg; 5 mg; 10 mg)

Drug Class

Calcium channel blockers

Pharmacokinetics

Absorption: Felodipine is rapidly absorbed from the gastrointestinal tract after oral administration. Due to its formulation as an extended-release tablet, felodipine provides a controlled absorption profile that leads to steady plasma concentrations over a 24-hour dosing interval, which aids in maintaining consistent antihypertensive effects. Peak plasma concentrations are typically reached within 1-3 hours post-dose. Oral bioavailability of felodipine is limited by extensive first-pass metabolism in the liver, reducing systemic availability to approximately 15-20%. Absorption may be affected by concomitant food intake, but clinical guidance allows administration with or without food provided consistency is maintained in dosing to avoid fluctuations.

Distribution: Felodipine exhibits a high degree of plasma protein binding (>99%), primarily to albumin, which contributes to its distribution characteristics. Its volume of distribution is moderate, reflecting extensive tissue binding in vascular smooth muscle. The drug crosses biological membranes to exert its vasodilatory effect on peripheral arterial smooth muscle. Due to its lipophilicity, felodipine accumulates within highly perfused tissues including the heart and lungs, supporting its pharmacodynamic effect.

Metabolism: Felodipine undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme CYP3A4. This metabolic pathway results in several inactive metabolites excreted mainly in bile. The high first-pass metabolism leads to low oral bioavailability and significant drug interactions when coadministered with CYP3A4 inhibitors or inducers, which can substantially alter plasma levels. Inducers such as rifampin reduce plasma concentrations by enhancing metabolism, while inhibitors like ketoconazole increase felodipine levels, potentially leading to toxicity.

Elimination: The metabolites of felodipine are primarily eliminated via biliary excretion into the feces, with a minor portion excreted renally. The elimination half-life is approximately 11 to 16 hours with extended-release formulations providing consistent plasma concentrations suitable for once-daily dosing. Renal impairment has minimal impact on clearance, but hepatic dysfunction may elevate plasma levels due to impaired metabolism, necessitating dose adjustments. Elimination kinetics support its usage in stable, long-term antihypertensive therapy with regular monitoring.

Dosage Forms

Available Dosage Forms: Felodipine is commercially available exclusively as an extended-release oral tablet designed for once-daily administration. The marketed dosages include 2.5 mg, 5 mg, and 10 mg tablets. These formulations employ a controlled-release matrix allowing gradual drug release to maintain consistent plasma levels over 24 hours, thereby optimizing blood pressure control and minimizing peak-related side effects.

Dosages for Adults and Adolescents: For adult patients with hypertension, the usual initial dose is 5 mg once daily, with maintenance doses ranging from 2.5 mg to 10 mg once daily. Dose titration should proceed cautiously, generally in intervals of at least two weeks to assess efficacy and tolerability. In geriatric patients, initial dosing may start lower, typically 2.5 to 5 mg once daily, with similar maintenance dose ranges. Adolescents and pediatric use is off-label and not FDA-approved; however, NIH and NHLBI guidelines suggest initiating at 2.5 mg once daily in patients aged one year and older, with maintenance dosing up to 10 mg daily, carefully monitored by specialists.

Specific Patient Populations: Dose adjustments are recommended for patients with hepatic impairment due to reduced metabolic clearance, which may increase plasma drug levels and risk of hypotension or other adverse effects. Renal impairment does not typically necessitate dosage modification. In pregnancy, felodipine has potential fetal risks and should be used only if clearly needed, with risk-benefit assessment by the physician. Breastfeeding mothers should consult healthcare providers as limited data exist regarding excretion into human milk. Consistent administration with respect to meals and avoidance of grapefruit products are important due to drug-food interactions influencing bioavailability.

Mechanism Of Action

Felodipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels located on vascular smooth muscle cells. By blocking the influx of extracellular calcium ions into these cells during depolarization, felodipine decreases intracellular calcium concentrations, which are necessary for muscle contraction. This inhibition results in relaxation of arterial smooth muscle, leading to vasodilation predominantly in peripheral arterioles.

This vasodilatory effect reduces systemic vascular resistance and arterial blood pressure without significantly affecting venous capacitance vessels. The decreased peripheral resistance reduces afterload and myocardial oxygen demand, thus indirectly benefiting cardiac function. Unlike non-dihydropyridine calcium channel blockers, felodipine exhibits minimal effects on cardiac conduction velocity or contractility, limiting the risk of negative chronotropic or inotropic effects.

On a cellular level, felodipine’s binding to L-type calcium channels occurs at specific sites within the channel pore, stabilizing the inactive conformational state and preventing calcium entry during the plateau phase of the action potential. This results in smooth muscle relaxation and decreases vascular tone. The drug's selective arterial vasodilation contributes to its effectiveness in lowering blood pressure as well as improving symptoms of angina and vasospastic conditions.

Clinical studies have demonstrated felodipine's efficacy in reducing systolic and diastolic blood pressure, with a favorable side effect profile relative to other antihypertensive agents. Compared to other calcium channel blockers like amlodipine, felodipine's extended-release formulation provides a smoother plasma concentration profile, contributing to better tolerability, particularly with regard to peripheral edema and reflex tachycardia. Ongoing research explores its potential utility in other vascular disorders due to its vasodilatory properties.

Pharmacological Actions

Potent arterial vasodilator reducing peripheral vascular resistance.
Selective inhibition of L-type calcium channels in vascular smooth muscle.
Lowers systemic arterial blood pressure effectively.
Minimal impact on cardiac conduction or contractility compared to other calcium channel blockers.
Reduces afterload and myocardial oxygen demand.
Improves coronary blood flow and relieves vasospasm.
Exhibits sustained antihypertensive effect with once-daily dosing.
Does not significantly affect venous capacitance vessels.
Demonstrates high plasma protein binding reducing free drug fluctuations.
Metabolized primarily by hepatic CYP3A4 enzymes.
Extended-release formulation reduces peak-related adverse effects.
Reduces systolic and diastolic blood pressure in essential hypertension.
Avoids pronounced negative inotropic effects, making it safer in certain cardiac conditions.
Produces peripheral vasodilation contributing to improved tissue perfusion.
Displays a favorable pharmacokinetic profile with a half-life supportive of consistent therapeutic effects.

Therapeutic Or Clinical Uses

Management of essential hypertension to lower high blood pressure.
Adjunctive therapy in combination with other antihypertensives for resistant hypertension.
Treatment of stable angina pectoris due to its vasodilatory effects.
Potential use in vasospastic angina to relieve coronary artery spasm.
Off-label use in pediatric hypertension as per NIH/NHLBI recommendations.
Management of conditions associated with increased peripheral vascular resistance.
Reducing afterload in patients with congestive heart failure under specialist care.
Prevention of stroke and myocardial infarction via effective blood pressure control.
Improvement of symptoms related to Raynaud’s phenomenon (vasospastic disorder).
Preservation of renal function by controlling systemic hypertension in chronic kidney disease.
Use in elderly hypertensive patients with appropriate dose adjustment.
Alternative calcium channel blocker in patients intolerant to other antihypertensives.
Part of multidrug regimens targeting complex cardiovascular risk profiles.
Reducing cardiovascular morbidity by maintaining blood pressure within target ranges.
Adjunct to lifestyle interventions including diet and exercise for hypertension management.

Side Or Adverse Effects

Peripheral edema manifesting as swelling in hands, arms, legs, or feet.
Headache of varying intensity, often transient.
Flushing characterized by sudden warmth or redness of the skin.
Dizziness particularly on standing, leading to orthostatic hypotension.
Weakness or fatigue potentially related to vasodilation.
Palpitations or reflex tachycardia in some patients.
Worsening chest pain (angina) in patients with coronary artery disease; requires urgent evaluation.
Rare hypersensitivity reactions including rash or urticaria.
Gastrointestinal disturbances such as nausea or abdominal discomfort.
Rare cases of elevated liver enzymes indicating hepatic stress.
Hypotension leading to light-headedness or syncope, especially on dose escalation.
Rare occurrences of gingival hyperplasia with long-term use.
Peripheral neuropathy symptoms reported infrequently.
Potential worsening of heart failure symptoms due to fluid retention.
Allergic reactions including swelling of face, lips, tongue, or throat requiring emergency attention.

Precautions

Use caution in patients with congestive heart failure; monitor closely for worsening symptoms.
Avoid abrupt discontinuation to prevent rebound hypertension.
Monitor blood pressure regularly to assess therapeutic response and avoid hypotension.
Adjust doses cautiously in elderly patients due to increased sensitivity and comorbid conditions.
Avoid use in patients with known hypersensitivity to felodipine or other dihydropyridines.
Inform patients about risk of dizziness and advise proper precautions to prevent falls.
Advise patients to maintain consistent dosing with respect to meals.
Instruct patients to avoid grapefruit and grapefruit juice due to risk of increased drug levels.
Careful use advised in hepatic impairment due to decreased metabolism and increased exposure.
Use during pregnancy only if potential benefits outweigh risks due to possible fetal harm.
Consider potential drug interactions, especially with CYP3A4 inhibitors or inducers.
Educate patients about importance of adherence despite asymptomatic nature of hypertension.
Regular dental hygiene recommended to prevent gingival hyperplasia.
Monitor for signs of peripheral edema and manage accordingly.
Closely observe patients with low baseline blood pressure for symptomatic hypotension.

Warnings

Do not use felodipine if allergic to it or other calcium channel blockers.
May cause serious hypersensitivity reactions including anaphylaxis.
Risk of worsening heart failure necessitates judicious use and monitoring.
Potential to cause symptomatic hypotension, especially in volume-depleted patients.
Avoid grapefruit products which significantly increase plasma felodipine concentrations leading to toxicity.
Use only as directed and do not adjust dose without physician consultation.
Pregnancy category indicates possible risk to fetus; use only if clearly needed and under medical supervision.
Patients may experience dizziness or lightheadedness, increasing risk of falls or accidents.
Overdose can cause severe hypotension and bradycardia requiring emergency treatment.
May exacerbate angina symptoms in certain patients; report new or worsening chest pain promptly.
Potential for drug interactions necessitates disclosure of all concurrent medications.
Not approved for use in children under 1 year; safety and efficacy not well established.
Use caution when co-administering with other antihypertensive or cardiovascular agents.
Abrupt discontinuation may cause rebound hypertension with associated cardiovascular risks.
Patients should be advised not to share medication and to store it securely out of reach of children.

Contraindication

Known hypersensitivity to felodipine or other dihydropyridine calcium channel blockers.
Severe aortic stenosis where vasodilation can precipitate cardiovascular collapse.
Cardiogenic shock or unstable angina where blood pressure maintenance is critical.
Pregnancy unless potential benefits outweigh risks; caution due to possible fetal harm.
Hypotension or hemodynamically unstable states contraindicating further blood pressure reduction.
Concomitant use with strong CYP3A4 inhibitors without appropriate dose adjustment.
Patients with severe hepatic impairment requiring specialist evaluation prior to use.
Avoid use in patients with known intolerance or idiosyncratic reaction to formulation excipients.
Patients with marked bradycardia or advanced heart block unless a pacemaker is present.
Not recommended in pediatric patients under one year due to lack of safety data.
Severe renal impairment is not a formal contraindication but requires monitoring.
Concurrent use with other vasodilators may be contraindicated depending on clinical condition.
Exclusion where symptomatic hypotension has previously necessitated discontinuation.
Do not use during hypertensive emergencies requiring rapid blood pressure control.
Contraindicated in patients who have shown hypersensitivity reactions such as angioedema.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) increase felodipine plasma levels, heightening risk of hypotension and side effects.
CYP3A4 inducers (e.g., rifampin, St. John's Wort) reduce felodipine plasma concentrations, potentially decreasing efficacy.
Concurrent use with other antihypertensive agents may cause additive blood pressure lowering effects leading to hypotension.
Grapefruit and grapefruit juice significantly inhibit CYP3A4 metabolism, increasing felodipine bioavailability and risk of adverse effects.
Co-administration with simvastatin may require monitoring due to CYP3A4 metabolism overlap.
Combination with beta-blockers may unmask or worsen bradycardia or AV block, requiring careful cardiovascular assessment.
Use with non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem) can increase risk of excessive hypotension and cardiac conduction disturbances.
Avoid concomitant use with strong CYP3A4 inhibitors in patients with compromised hepatic function.
May increase concentration of drugs metabolized by CYP3A4 due to competitive inhibition.
Use with medications affecting blood pressure, such as nitrates or diuretics, may potentiate hypotensive effects requiring dose adjustment.
Careful monitoring advised when combined with immunosuppressants like cyclosporine due to CYP3A4 interactions.
Potential interaction with digoxin necessitates monitoring for changes in digoxin levels.
Co-use with alcohol may exacerbate vasodilatory side effects and hypotension.
Patients on multiple medications should have thorough medication reviews to assess cumulative interactions.
Herbal supplements affecting CYP3A4 activity (e.g., goldenseal) may alter felodipine pharmacokinetics.

Preparations Of The Drug

Extended-release oral tablets formulated for once-daily administration to ensure stable plasma concentrations.
Available in 2.5 mg, 5 mg, and 10 mg strengths to allow flexible dose individualization.
Tablets designed to be swallowed whole; crushing or breaking is contraindicated to avoid dose dumping.
Packaging designed to protect from moisture, heat, and light to maintain drug stability.
Formulations include excipients compatible with sustained-release mechanisms to minimize peak-related adverse events.
Commercial brands predominantly include Plendil as the primary marketed product.
Manufactured under stringent quality control to ensure consistent drug release profiles.
Storage requirements specify room temperature away from excessive moisture and heat sources.
Patient information leaflets emphasize adherence to dosing schedule and precautions regarding food interactions.
Some generic formulations may exist but should retain equivalent pharmacokinetic profiles to brand-name products.
Available only by prescription to ensure medical supervision of use and monitoring.
Prepared in dose strengths enabling titration to achieve desired therapeutic effects with minimal side effects.
Packaging often includes calendar blister packs or bottles with dosing instructions to improve compliance.
No injectable or intravenous forms currently available; exclusively oral administration.
Pre-marketing formulation studies ensure consistent drug release and absorption characteristics.